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https://doi.org/10.1016/j.ccell.2018.02.011SUMMARYGenetic linkage analysis previously suggested that GKAP, a scaffold protein of the N-methyl-D-aspartate
receptor (NMDAR), was a potential modifier of invasion in a mouse model of pancreatic neuroendocrine
tumor (PanNET). Here, we establish that GKAP governs invasive growth and treatment response to
NMDAR inhibitors of PanNET via its pivotal role in regulating NMDAR pathway activity. Combining genetic
knockdown of GKAP and pharmacological inhibition of NMDAR, we implicate as downstream effectors
FMRP and HSF1, which along with GKAP demonstrably support invasiveness of PanNET and pancreatic
ductal adenocarcinoma cancer cells. Furthermore, we distilled genome-wide expression profiles orches-
trated by the NMDAR-GKAP signaling axis, identifying transcriptome signatures in tumors with low/
inhibited NMDAR activity that significantly associate with favorable patient prognosis in several can-
cer types.INTRODUCTION
While distinct oncogenic ‘‘driver’’ genes are widely appreciated
to be instrumental in cancer progression, the contributions of
‘‘modifier genes’’ have been less well studied. Modifier genes
can alter the penetrance of specific driver oncogenes, exertingSignificance
Genetic linkage analyses have associated multiple cancer mod
and responses to treatment. However, functional validation of c
underlyingmechanistic basis limited. In this proof-of-concept s
from distinct strain backgrounds to explore the validation pr
Dlgap1 (which encodes GKAP protein), suggested by genetic li
of invasive growth orchestrated by NMDAR signaling. Using re
tumors lacking NMDAR-GKAP pathway activity that predict
broader involvement of this pathway in malignancy.
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however, few of these genetic modifiers have been validated
mechanistically. Elucidating how genetic polymorphisms affectifier loci with disease susceptibility, malignant phenotypes,
ancer modifier genes has been challenging and insights into
tudy, we used genetically engineeredmousemodels derived
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tumorigenesis at the molecular level is an important step toward
appreciating individual variation in prognosis and in implement-
ing personalized cancer therapies.
The RIP1Tag2 transgenic mouse model of pancreatic neuro-
endocrine tumor (PanNET) recapitulates the multi-stage nature
of human cancer progression. As such, it has proved to be a
valuable research tool for elucidatingmechanisms of tumor inva-
sion and growth. Interestingly, varying degrees of tumor inva-
siveness are observed at end stage depending on the genetic
background in which the same transgene integration is resident,
despite expressing similar levels of the driving oncoprotein
(SV40 T-antigen) under control of the rat insulin promoter (RIP).
In particular, the C57BL/6 (B6) background gives rise to highly
invasive carcinomas, whereas mice in the C3HeB/Fe (C3H)
background primarily develop well-defined, non-invasive islet
tumors (Chun et al., 2010). Therefore, the RIP1Tag2 model
may phenocopy a facet of the complexity of cancer progression
in patients, where the same oncogenetic events can lead to vary-
ing outcomes in different patient populations.
Motivated by this observation, a classical linkage analysis
was performed, identifying a QTL on mouse chromosome 17
that is highly associated with the invasive phenotype. As
such, it was postulated to be a candidate ‘‘modifier locus’’ for
mPanNET progression (Chun et al., 2010). This 13-Mb region
harbors more than 50 genes; notably, there are no polymorphic
differences in their coding regions, which led to a focus on dif-
ferential expression. Among these genes, we became intrigued
by Dlgap1, encoding GKAP, which serves as a key adaptor pro-
tein of the glutamate-activated N-methyl-D-aspartate (NMDA)
receptors (NMDARs, also known as GluNRs). NMDAR is an
important neuronal receptor involved in learning and memory,
regulating synaptic plasticity in the central nervous system
(Abbott and Nelson, 2000). As a first step, before evaluating
GKAP itself, we asked in an earlier study whether NMDAR
signaling was activated and, if so, was it influencing invasive
tumor growth in the pro-invasive B6 background of this
mouse model of PanNET, where GKAP was more highly ex-
pressed. Indeed, we established that the pathway was
activated and that glutamate stimulated NMDAR activity and
invasive tumor growth (Li and Hanahan, 2013). These findings
prompted the current investigation to ascertain whether
GKAP was a potential modifier gene whose differential expres-
sion contributes to genetic background-specific differences in
pancreatic tumor invasiveness.
RESULTS
Dlgap1 Is the Most Differentially Expressed Candidate
Modifier Gene between the Invasive B6 and Non-
invasive C3H Backgrounds
Initially, we further mined the expression data from Chun et al.
(2010) and found Dlgap1 (encoding the GKAP protein) to be
the most differentially expressed gene within the modifier locus,
both in normal pancreatic islets and in fully developed b cell tu-
mors (PanNETs) (Figure S1A). Interestingly, in wild-type animals,
qRT-PCR also revealed elevated Dlgap1 expression in a number
of B6 tissues when compared with C3H tissues (Figure S1B).
In vitro, PanNET cell lines (bTC) derived from each of the two
strains showed a clear difference in GKAP transcripts, withhigher levels in bTC-B6 than in bTC-C3H (Figure 1A), consistent
with the qRT-PCR analysis of fluorescence-activated cell sorting
(FACS)-purified cells from primary PanNETs, which revealed b
tumor cells to be the major Dlgap1-expressing cell population
compared with associated stromal cells (Figures 1B and S1C).
We next sought to investigate the basis for the elevated
expression of GKAP in B6 tissues, focusing on potential regula-
tory polymorphisms, given that there were no differences in
the coding region of Dlgap1 between B6 and C3H. Genomic
analysis for single nucleotide polymorphisms (SNP) in putative
transcription factor-binding sites within 5Kb upstream and
downstream of Dlgap1 identified a SNP (rs33397766) that
maps to a potential heat shock factor (HSF)-binding element
(Figure 1C, upper panel). While the consensus HSF1 binding
site is TTCnnGAAnnTTC (http://hocomoco11.autosome.ru/
motif/HSF1_HUMAN.H11MO.0.A), some studies have shown
that, while the TTC repeats at each end are highly conserved,
the internal GAA site can be variable (http://stormo.wustl.edu/
ScerTF/details/HSF1/). Notably, the B6 allele of Dlgap1
(ATTCTCTTCTCTTCT) has TTC repeats at each end of this puta-
tive HSF1 site and is therefore predicted to enable HSF1 binding
(p < 0.004). In contrast, the C3H allele of this site in Dlgap1 lacks
the second TCC repeat due to the SNP variation, which can be
predicted to impair HSF1 binding. Indeed, chromatin immuno-
precipitation (ChIP) qPCR in bTC-B6 and bTC-C3H mPanNET
cell lines showed enrichment of HSF1 binding at the proposed
site within Dlgap1 in B6 compared with C3H (Figure 1C, lower
panel). Furthermore, GKAP expression was decreased when
we knocked down HSF1 in bTC-B6 cells (Figure 1D), suggesting
that HSF1 is an upstream regulator of GKAP.
Cancer Cells from the Invasive B6 Background Have
Higher NMDAR Pathway Activity than Those from the
Non-invasive C3H Background
We previously established an invasion assay mimicking intersti-
tial pressure-driven fluid flow that activates glutamate secretion
and NMDAR signaling, thereby enhancing invasiveness (Li and
Hanahan, 2013). Using this assay, we found that B6 cancer cells
(bTC-B6) were more invasive than C3H cancer cells (bTC-C3H)
(Figure 1E). Moreover, while bTC-B6 and bTC-C3H had similar
levels of glutamate secretion under static conditions, flow condi-
tions selectively enhanced glutamate secretion by bTC-B6
compared with bTC-C3H (Figure 1F).
In its capacity as a transmembrane calcium channel, activa-
tion of NMDAR by glutamate leads to calcium influx into the
cell. Therefore, we used a fluorescent calcium indicator to
assess the functionality of NMDAR in bTC-B6 and bTC-C3H cul-
tures (Figure 2A). As the name implies, the synthetic amino acid
NMDA is a highly specific and potent ligand for NMDAR, and
NMDAR is its only known receptor; as such, a response to
NMDA is indicative of a functional NMDAR. When we applied
NMDA to cultured cancer cells in puffs from a micropipette, a
strong signal for calcium influx was observed in bTC-B6 cells,
whereas no signal was detectable in bTC-C3H (Figure 2B), indi-
cating the presence of functional NMDA-responding calcium
channels (i.e., NMDAR) in bTC-B6 but not in bTC-C3H. This
finding was further confirmed with whole-cell patch-clamp
recording, in which application with a micropipette of the
synthetic ligand NMDA or of glutamate resulted in NMDARCancer Cell 33, 736–751, April 9, 2018 737
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Figure 1. Differential GKAP Expression between the C57/BL6 and C3HeB/Fe Genetic Backgrounds Is Associated with a Differential NMDAR
Pathway Activity In Vitro
(A) qRT-PCR of Dlgap1mRNA (upper) and western blot for GKAP protein expression (lower) in mPanNET tumor-derived cancer cell lines (bTC-B6 and bTC-C3H)
or primary tumors that arose in RIP1Tag2 transgenic mice inbred into the B6 and C3H backgrounds, respectively. *p < 0.05; **p < 0.01 (n = 3 individual tumors/
genetic background; n = 3 independent RNA extraction/cell line).
(B) qRT-PCR analysis of FACS-sorted cell types from primary tumors derived from B6 mice. Cells were sorted from pools of multiple PanNETs isolated from two
mice. One-way ANOVA, Dunnett multiple comparisons test was usedwhen cancer cells were comparedwith all other populations (p < 0.0001 in all comparisons).
(C) Upper panel: a region within the Dlgap1 gene sequence containing a SNP site, as shown in red. Putative HSF1 binding domains (p < 0.004) are shown by the
green circles. Lower panel: ChIP-qPCR for the Dlgap1 SNP site after immunoprecipitation with an anti-HSF1 antibody. The bmaj (b globin, Hbb-b1) promoter
region was used as negative control. Mann-Whitney test: *p = 0.02 (n = 4, two batches of cell lysates per cell line, and two qPCR/batch).
(D) Western blot for HSF1 and GKAP in bTC-B6 cells. Expression levels were normalized to GAPDH and small interfering RNA (siRNA) control (n = 3 independent
experiments).
(E) In vitro invasion assay of bTC-B6 and bTC-C3H cells, under either static or flow conditions. Two-way ANOVA, Bonferroni multiple comparisons test: n.s, not
significant; ***p < 0.001 (n = 4 independent assays for static condition; n = 6–9 for flow condition).
(F) Glutamate secretion by bTC-B6 and bTC-C3H cells under static and flow conditions, sampled from invasion assays. Two-way ANOVA, Bonferroni multiple
comparisons test: ***p < 0.001; ****p < 0.0001; n.s., not significant (n = 3 invasion assay devices/condition/cell line).
All bar graphs represent the mean ± SEM. See also Figure S1.activation only in bTC-B6 but not in bTC-C3H (Figures 2C and
2D). Furthermore, intracellular perfusion of glutamate through a
membrane-sealed micropipette in the whole-cell patch-clamp
configuration activated the surface-localized NMDAR in bTC-
B6, suggestive of autocrine glutamate secretion from the
perfused bTC-B6 cells (Figures 2E and 2F), congruent with a pre-
vious report (Robinson and Li, 2017). Notably, besides being
distinct in NMDAR activity, the electrophysiology and passive
membrane properties in these two cell lines were similar (Fig-
ure 2G), and consistent with previous analyses of normal b cells.
GKAP Expression Is Associated with Differential
NMDAR Activity and Sensitivity to Pharmacological
Inhibition In Vivo
We went on to evaluate the NMDAR pathway in PanNETs that
had arisen de novo in RIP1Tag2 mice from the two strain back-738 Cancer Cell 33, 736–751, April 9, 2018grounds. The NMDAR includes both GluN1 and GluN2 subunits,
of which GluN2b interacts with GKAP. We found that both GluN1
(encoded by Grin1) and GluN2b (encoded by Grin2b) were ex-
pressed in B6 and C3H PanNETs at comparable levels, yet
GKAP was significantly lower in the C3H background (Figures
3A and B). Notably, while GluN2b was expressed at similar levels
in PanNETs from both strain backgrounds (Figures 3B and 3C),
p-GluN2b (at Y1252), an indicator of NMDAR activation, was
only detectable in B6 but not in C3H PanNETs (Figure 3C).
Consistently, C3H RIP1Tag2 mice were largely non-responsive
in a pharmacological ‘‘intervention’’ trial using the NMDAR inhib-
itor MK801, in contrast with B6 RIP1Tag2 mice (Figure 3D). The
result establishes that, despite similar expression levels of
NMDARmRNA and protein in PanNETs from both genetic back-
grounds, comparatively elevated expression of the scaffold pro-
tein GKAP in B6 PanNETs was associated with higher signaling
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Figure 2. Intracellular Calcium Responses and Electrophysiology Reveals Functional NMDAR in bTC-B6 but Not in bTC-C3H Cells
(A) Oregon Green-labeled calcium indicator BAPTA-AMwas applied to bTC-B6 and bTC-C3H cancer cells bathed in aMg-free Ringer solution; puffing an NMDA
solution (1mM, 1 s, through perfusion pipette at left) induced calcium influx into the cells, thereby producing an increased fluorescence signal (DF) comparedwith
the background fluorescence signal (F). The top left image shows bTC-B6 in phase-contrast, whereas the lower left image shows a green-fluorescence signal
overlaid with a phase-contrast image. The graph at the right shows time-resolved fluorescence signals (sampling frequency/frame rate = 12.5 Hz), where each
trace represents one recorded cell. The y axis indicates the change in fluorescence intensity.
(B) Using the fluorescence reporter assay in (A), the number of bTC cells with active NMDAR signaling was determined following puff application of 1 mMNMDA.
The DF/F measurements refer to the normalized difference in each cell’s signal measured immediately before the application of agonist compared with the peak
of the response after the puff. For bTC-B6, 263 cells from 15 different regions of three independent culture dishes were recorded. Light green bar indicates cells
with no response; dark green bars indicate cells with DF. For bTC-C3H, 155 cells from eight regions of two different dishes were analyzed. Wilcoxon rank-sum
test, p < 4.24e16.
(legend continued on next page)
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activity, and hence increased sensitivity to pharmacological inhi-
bition. Notably, given that C3H RIP1Tag2 mice have appreciably
higher tumor burden compared with B6 RIP1Tag2 mice and that
no QTL locus associated with tumor burden (Chun et al., 2010),
we conclude that alternative pathways are activated in C3H tu-
mors to promote tumor growth and proliferation independent
of the NMDAR-GKAP pathway.
GKAP Knockdown Phenocopies the ‘‘Low NMDAR
Activity’’ Status and Reduces Invasiveness of mPanNET
Cells In Vitro
The qRT-PCR data implied that the comparatively higher levels
of GKAP in B6 cancer cells might be required for activation of
glutamate secretion and NMDAR signaling, as GKAP was the
only differentially expressed gene from the core NMDAR
signaling axis (Figure 3A). We therefore evaluated the impact of
GKAP knockdown onNMDARpathway activity and cell invasive-
ness in PanNET cancer cells (bTC-3) (Figures 4A and S2A).
Indeed, the GKAP-knockdown cells showed decreased GluN2b
phosphorylation, indicative of reduced NMDAR signaling activity
(Figure 4A). Furthermore, GKAP-knockdown cells exhibited a
significantly reduced response to theNMDA ligand in the fluores-
cent calcium indicator assay (Figure 4B) and decreased inva-
siveness under flow conditions (Figure 4C). Thus, the GKAP
knockdown functionally phenocopied the C3H phenotype, in
relation to NMDAR activity and cancer cell invasiveness.
NMDAR Signaling Modulates FMRP and HSF1
In neurons, NMDAR signaling governs synaptic plasticity
through regulating local protein translation, for which the
mRNA-binding protein FMRP (fragile X mental retardation pro-
tein) is critical (Hoeffer and Klann, 2009). Moreover, in neurons,
NMDAR activity has been shown to increase FMRP protein
expression (Gabel et al., 2004; Todd et al., 2003). Interestingly,
a previous study demonstrated that FMRP promoted invasive-
ness and metastasis of breast cancer cells (Luca´ et al., 2013),
although the upstream signaling events leading to FMRP activa-
tion were unexplored. Therefore, we took a candidate gene
approach to investigate FMRP as a potential downstream target
of NMDAR signaling in mPanNET.
We found higher FMRP protein expression in B6 tumors
compared with C3H tumors (Figure S2B); moreover, in B6
mPanNETs, FMRP expression was particularly elevated in
more invasive tumors (Figures 4D, S2C, and S2D) and in liver
metastases (Figure 4D). Consistently, knocking down FMRP
decreased bTC-3 invasion in vitro (Figure 4E). Interestingly, while
FMRP mRNA showed modest stepwise upregulation during(C) Left: exogenous application of 1 mM NMDA to bTC-B6 cells, using a puffer p
whole-cell recording, holding at90mV.) Right: exogenous application of 500 mM
bTC-C3H cells.
(D) L-Glutamate application to bTC-B6 cancer cells. Three successive membrane
solution, with a membrane potential of 80 mV (upper panel); voltage-respons
recording) mode (lower panel).
(E) Intracellular glutamate perfusion during low-noisewhole-cell recordings to asse
A segment at higher time resolution is shown at bottom, as indicated. Right: bTC-
three different cells.
(F) Current amplitude histogram of autocrine-activated NMDARs in a bTC-B6 ce
(indicated by arrows) with a chord conductance of 48 pS, assuming reversal at 0
(G) Current-clamp recordings with step current injection in bTC-B6 (left) and bTC
740 Cancer Cell 33, 736–751, April 9, 2018PanNET tumorigenesis according to data from a published data-
set (Sadanandam et al., 2015) (Figure S2E), the upregulation of
FMRP protein in liver metastases when compared with primary
tumors was far more impressive (Figures 4D and S2F). This result
is consistent with observations in neurons that upregulation of
FMRP by NMDAR signaling is largely post-transcriptional (Gabel
et al., 2004; Todd et al., 2003).
Intriguingly, previously reported RIP-chip (ribonucleoprotein
immunoprecipitation followed by microarray analysis) data
showed that FMRP binds to HSF1 mRNA (Ascano et al.,
2012). Moreover, both HSF1 and FMRP are known to play
important roles in translational regulation (Darnell and Klann,
2013; Santagata et al., 2013). Therefore, we asked whether
targeting the NMDAR pathway might also affect HSF1 activa-
tion. Indeed, inhibition of NMDAR either by MK801 treatment
or by GKAP knockdown decreased both FMRP expression
and HSF1 phosphorylation at S326, a marker for its activation
(Figure 4F), which was recapitulated by MK801 treatment
in vivo (Figure 4G). Notably, mRNA levels for FMRP (Fmr1)
remain unchanged after GKAP knockdown or MK801 treat-
ment (Figures S2G and S2H), in contrast to the evident reduc-
tion in levels of the protein. Collectively, the data presented
above establish GKAP as a genetically polymorphic modifier
that differentially regulates an invasive growth program medi-
ated by NMDAR signaling as a function of differential expres-
sion governed by genetic background, evidently involving
HSF1 and FMRP.
NMDAR Activity in PDAC: a Similar Signaling Axis
Uncovered
Next we sought to investigate whether NMDAR activation
through GKAP and the consequent upregulation of FMRP/
HSF1 could be important for other cancer types. We focused
on an appraisal of pancreatic ductal adenocarcinoma (PDAC),
in which NMDAR was previously implicated (Li and Hanahan,
2013). We selected two mPDAC cell lines to represent high
and low GKAP protein expression. Western blots revealed that
the GKAPhigh line (mPDAC-4361) had elevated p-GluN2b
compared with the GKAPlow line (mPDAC-2263) (Figure 5A),
which was correlated with increased invasiveness, especially
under flow conditions (Figure 5A), as well as with increased
sensitivity to MK801 inhibition (Figure 5B). Concordantly, knock-
ing down GKAP diminished GluN2b phosphorylation and damp-
ened invasion of the GKAPhigh cell line (Figure 5C). Moreover,
p-HSF1 was significantly decreased by GKAP knockdown, while
the effect on FMRP levels was marginal (Figure 5C), perhaps
reflective of the incomplete knockdown. Congruent resultsipette pressure application during the period shown by gray bar. (Low-noise
NMDA (two cells), 1 mMNMDA (seven cells), or glutamate (50 mM, four cells) to
current responses (in voltage-clamp mode) are shown, using Mg-free Ringer
e, including action potentials, was measured in current-clamp (i.e., voltage
ss autocrine activation of NMDARs in bTC cells. Left: bTC-B6 cells, n = 12 cells.
C3H cells, n = 9 cells. (a–c) Representative segments of recording from one of
ll, showing peaks corresponding with single and double openings of channels
mV.
-C3H (right).
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Figure 3. High GKAP Expression Is Associated with Increased NMDAR Pathway Activity In Vivo
(A) qRT-PCR evaluation for the NMDAR subunits GluN1 (Grin1), GluN2b (Grin2b), and the scaffold protein GKAP (Dlgap1) in PanNET tumors from the two genetic
backgrounds. Mean ± SEM. Mann-Whitney test was used to compare the expression of each gene in the B6 and C3H tumors. *p = 0.0175 (qRT-PCR: n = 7
tumors/7 mice/background).
(B) Western blot of GluN2b and GKAP in PanNETs from B6 and C3H backgrounds. After normalization, the one-column t test was used for comparison,
hypothetical value = 1; *p = 0.01; n.s., not significant (mean ± SEM; n = 4 tumors/4 mice).
(C) Immunohistochemistry (IHC) analysis of large T oncoprotein, GluN2b, and p-GluN2b in PanNET tumor tissue sections. Images are representative of >50
tumors from >10 RIP1Tag2 mice/background. S, spleen; LN, lymph node.
(D) MK801 treatment in RIP1Tag2 mice. Cohorts of seven to nine mice were used for control (saline treated) and MK801 treatment in each genetic background;
mean ± SEM. Mann-Whitney test: **p < 0.01; n.s., not significant.were observed in two hPDAC cell lines, DanG and SUIT2, in
which GKAP knockdown and MK801 treatment both decreased
hPDAC invasiveness (Figure 5D). MK801 treatment also
decreased HSF1 phosphorylation and FMRP expression (Fig-
ure 5E). Finally, knocking down either FMRP or HSF1 in hPDAC
cells decreased hPDAC invasiveness in the flow-stimulated inva-
sion assay (Figure 5F).
Next, immunostaining of tumor sections from the PDAC
genetically-engineered mouse model (GEMM) revealed that
p-GluN2b, GKAP, HSF1, and FMRP were all highly expressed
both in primary tumors and in liver metastases (Figure 6A).
Furthermore, in human tissue microarrays (TMAs) of PDAC,the expressions of p-GluN2b, GKAP, HSF1, and FRMP all
showed a trend of progressive elevation from primary PDAC
to lymph node metastases (Figure 6B). Moreover, p-GluN2b
was positively associated with GKAP expression (Figure 6C),
in further support of the conclusion that variable GKAP expres-
sion modulates NMDAR signaling activities in hPDAC. Notably,
p-GluN2b also correlated with HSF1 and FMRP expression,
with larger tumor size (Figure 6C), and with vascular invasion
(Figure 6D). In contrast to PanNET, where GKAP was constitu-
tively expressed at similar levels in the normal pancreatic islets
and throughout multistep tumorigenesis (Sadanandam et al.,
2015), GKAP was evidently upregulated during the malignantCancer Cell 33, 736–751, April 9, 2018 741
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progression in PDAC (Figure 6B), suggesting a distinctive mode
of gene regulation.
Transcriptome Profiling Reveals Gene Signatures for
Inhibition of NMDAR Signaling
Collectively, our data revealed extensive regulations of the
NMDAR signaling axis that are independent of mRNA expres-
sion, including phosphorylation (GluNR2b, HSF1), translation
(FMRP), in addition to differential binding to DNA (HSF1). While
the results from the TMA analysis were informative, immuno-
staining of patient samples to ascertain NMDAR activity is both
time consuming and labor intensive, and often limited by the
paucity of appropriate clinical samples. Therefore, we sought
to identify gene expression signatures that might be reflective
of differential NMDAR activity, by analyzing RNA sequencing
(RNA-seq) data from B6 mPanNETs, B6 MK801-treated
mPanNETs, and C3H mPanNETs (Figure 7A).
First, we identified a ‘‘strain signature’’ that distinguished un-
treated B6 tumor samples from C3H tumor samples (Figure 7B
and Table S1). Signature correlation values were represented
as Z scores. The higher a jZj score is, the more likely that the
gene is a major factor (driver) in the signature. In our analysis,
genes with jZj > 2.5 were considered to be significantly associ-
ated with their corresponding signature. Importantly, Dlgap1
(jZj = 9.6) was the second most poorly expressed gene in C3H
(Figure 7B), consistent with Dlgap1 being a potential pheno-
type-defining gene distinguishing B6 versus C3H PanNETs.
Notably,Dlgap1 has nine differentially spiced protein-coding iso-
forms, of which three were detected by RNA-seq, and all three
were differentially expressed between B6 and C3H PanNETs
(Figure S3A). Next, we identified a set of 330 genes that distin-
guished MK801-treated B6 tumors from untreated B6 tumors
(‘‘MK801 treatment signature’’, Figure 7C, Tables S2, and S3).
Gene set enrichment analysis (GSEA) (Subramanian et al.,
2005) between the ‘‘strain signature’’ and the ‘‘MK801 treatmentFigure 4. GKAP Regulates Cancer Cell Invasion through NMDAR Activ
(A) Western blot for GKAP and p-GluN2b in control and GKAP-knockdown bTC-3
levels of p-GluN2b and GKAP normalized to untransfected bTC-3.
(B) Fluorescence reporter assay was performed in bTC-3 small hairpin RNA (shRN
induced by puffing an NMDA solution onto the cells. Clusters of cultured contro
croscope after anNMDA solution (1mM, 1 s) was puffed through perfusion pipette
control KD cells: 78 of 284 cells examined showed a response (orange bars). bTC
blue bars). p < 1011, Wilcoxon rank-sum test. Histogram of transient amplitude,
12.5 Hz). Light orange bar and blue bar indicate cells with no response.
(C) Invasion assay in control and GKAP-KD bTC-3 cells. Two-way ANOVA, Bonfe
n = 3 invasion assay devices/condition in one experiment; two independent exp
(D) IHC staining of FMRP in B6 PanNETs. Similarly sized invasive versus non-in
borders marked by yellow dashed line in the representative images). Rare, m
arrowheads, tumor borders marked by yellow dashed line). Images shown are re
section per mouse, and all staining was performed in the same experiment. Mag
(E) Western blot shows the efficiency of FMRP knockdown in bTC-3 cells. The num
assay. Unpaired t test: *p < 0.05; **p < 0.01. FMRP #1 and #2 indicate two different
in one experiment; two independent experiments).
(F) Western blots comparing FMRP and p-HSF1 expression in bTC-3 cancer c
comparing expression of p-GluN2b, FMRP, and p-HSF1 in bTC-3 cancer cells tre
and the numbers below indicate levels of p-GluN2b, FMRP, and p-HSF1 normal
(G) Left: tissue immunostaining shows expression of total and active GluN2b, FM
RIP1Tag2 mice. Data shown are representative of 9–21 random pictures from >
resents 25 mm. Right: quantification of FMRP and pHSF1 expression in saline- an
groups, n = 21 inMK801-treated group; p-HSF1, n = 15 pictures in saline treated g
See also Figure S2.signature’’ revealed striking similarity between the two signa-
tures (Figure 7D), suggesting that C3H tumors were similar to
MK801-treated B6 tumors when compared with B6 control tu-
mors, which further supported our hypothesis that differences
in NMDAR pathway activity are indeed among the defining char-
acteristics distinguishing B6 and C3H PanNETs.
The similarity between these two datasets led us to perform
GSEA leading edge analysis (Subramanian et al., 2005) to iden-
tify an ‘‘NMDAR-pathwaylow signature’’, which encompassed
common driver genes in both strain signature and MK801 signa-
ture (i.e., high in B6 control, low in both MK801-treated and C3H
samples, or vice versa) (Figure 7E and Table S4). Pathway ana-
lyses of the NMDAR-pathwaylow signature highlighted neuro-
genesis and synaptogenesis (Figure S3B), consistent with an
expectation for genes regulated by NMDAR signaling. Notably,
one of the major phenotypes of MK801-treated B6 tumors was
decreased proliferation and hence lower tumor burden, in
contrast to highly proliferative C3H tumors (Figure 7A). There-
fore, selecting for genes that were similarly expressed in both
C3H andMK801-treated B6 tumors allowed us to filter out genes
commonly associated with cell proliferation and focus on genes
more specifically reflecting NMDAR pathway activation.
Gene Expression Signatures for Low NMDAR Activity
Predict Better Patient Survival in Multiple Cancer Types
As a prelude to assessing prognostic associations, we per-
formed survival trials in the PDAC GEMM using MK801 and a
clinically approved, albeit less potent and less toxic, NMDAR in-
hibitor, memantine. Both inhibitors prolonged survival in treated
animals (Figure 8A), establishing that NMDAR inhibition is thera-
peutically beneficial for treating PDAC in a mouse model, as pre-
viously shown for PanNET (Li and Hanahan, 2013). We then
employed the MK801 treatment signature to query The Cancer
Genome Atlas (TCGA) database for associated survival differ-
ences. A significant survival benefit was associated with PDACity and Downstream Effectors FMRP and HSF1
cells under unstimulated cell culture conditions. The numbers below indicate
A) control and GKAP-knockdown (KD) cells lines, comparing calcium transients
l bTC-3 cells or GKAP-KD bTC-3 cells were analyzed under a bright-field mi-
at left (upper panels). The arrows indicate the direction of puffing. bTC-3 shRNA
-3 shRNA-GKAP KD cells: 5 of 178 cells showed minor NMDA responses (light
denoting time-resolved fluorescence signals (sampling frequency/frame rate =
rroni multiple comparisons test: **p < 0.01; n.s., not significant (mean ± SEM,
eriments were performed with consistent results).
vasive primary tumors on the same section were used for comparison (tumor
ultiple metastatic lesions in the liver from one mouse (indicated by the red
presentative of an analysis of >50 PanNETs from >10 B6 RIP1Tag2 mice, one
nified lesion is representative of >100 metastases from one liver.
bers below indicate levels of FMRP normalized to GAPDH. Bar graph: invasion
siRNA constructs used (mean ± SD, n = 3 invasion assay devices per condition
ells infected with control shRNA or shRNA-GKAP lentiviral vectors (left), and
ated with either vehicle or MK801 (right). GAPDH was used as a loading control
ized to GAPDH. (n = 3).
RP, and total and active HSF1 in tumors from saline- and MK801-treated B6
15 PanNETs from three mice per group. Scale bar in the blow-up picture rep-
d MK801-treated tumors. Mean ± SEM. FMRP, n = 9 pictures in saline treated
roups, n = 20 inMK801-treated group.Mann-Whitney test: *p < 0.05; **p < 0.01.
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patients whose tumors correlated with the MK801 treatment
signature, as if tumors from these patients had been treated
with MK801, compared with the rest of the patients (Figure 8B).
Moreover, lower-grade tumors (T1/T2) were better associated
with the MK801 treatment signature compared with higher-
grade tumors (T3/T4) (Figure S4A). Cox proportional hazards
regression analysis identified the MK801 treatment signature
as a significant, independent prognostic factor, while controlling
for other covariates (including T and N stage classification) in a
multivariable model (Figure 8C).
In addition to PDAC, this MK801 treatment signature was also
significantly associated with favorable prognosis in patients with
several other cancer types (Figures 8D and S4B). Furthermore,
among glial brain cancers, low-grade gliomas were significantly
more correlated with the MK801 treatment signature when
compared with advanced (more invasive and aggressive) glio-
blastomas (Figure 8E).
We described above (Figure 7E) a sub-signature of the MK801
treatment signature, the NMDAR-pathwaylow signature, which
encompassed driver genes common between the C3H strain
signature and the B6-MK801 treatment signature but lacked
common proliferation-associated genes that were asynchro-
nous between highly proliferative C3H and poorly proliferative
MK801-treated tumors. Analysis of the same patient tumor data-
sets revealed that this 148 gene NMDAR-pathwaylow signature
could also predict survival in PDAC patients (Figure 8F) and other
cancer types (Figures 8G and S4C), comparable with the associ-
ations revealed by the 330 genes in the full MK801 treatment
signature. The results suggest that our approach for identifying
phenotype-distinguishing signatures can bypass the obstacle
imposed by the extensive post-transcriptional modification of
the core NMDAR signaling components and their minimal tran-
scriptional variation, thus presenting a robust and effective
method for identifying tumors with high versus low NMDAR
pathway activity.
In sum, these data begin to broaden the association of
NMDAR signaling (via GKAP, HSF1, and FMRP) with invasive tu-
mor growth and malignancy. The results additionally suggest
that NMDAR antagonists may be therapeutically beneficial in
PDAC and other cancer patients whose tumors are inferred to
have elevated NMDAR signaling by virtue of lacking this favor-
able ‘‘NMDARlow’’ MK801 treatment signature.Figure 5. NMDAR Signaling through GKAP Promotes Invasion in Both
(A) Left panels: western blot analysis of GKAP and p-GluN2b levels inmPDAC-436
panel: invasion assay in static and flow-stimulated conditions. Two-way ANOVA
SEM, n = 3 invasion assay devices per condition per cell line in one experiment;
(B) MK801 treatment of mPDAC cell lines in static and flow-stimulated invasion a
static/flow conditions. Two-way ANOVA, Bonferroni’s multiple comparisons test
condition per cell line in one experiment; two independent experiments).
(C and D) GKAP mRNA was knocked-down in mPDAC-4361 (C) and in two hPDA
western blot analysis; numbers below indicate levels of GKAP normalized to GA
sentative images of DAPI-stained nuclei from the invasion assay illustrate the cells
100 mm) (C). Two-way ANOVA, Bonferroni’s multiple comparisons test (C) or unpa
assays: n = 3 invasion assay devices per condition in one experiment. Mean ± S
(E) Western blot analysis of p-HSF1 and FMRP levels in control and MK801-tre
normalized to GAPDH (n = 3).
(F) Western blot analysis assessing siRNA-mediated HSF1 and FMRP knockdown
indicate levels of HSF1 and FMRP normalized to GAPDH. Flow-guided-invasion a
on the right). Mean ± SEM, unpaired t test: *p < 0.05; **p < 0.01 (n = 3 invasion as
performed with consistent results.DISCUSSION
It is well recognized that genetic background can have signifi-
cant impact on cancer susceptibility, progression, and response
to treatment, both in humans and in mice. Here, we present
evidence that expression of the intracellular signal transducer
GKAP modulates activity of the glutamate-to-NMDAR signaling
pathway in the genetically engineered RIP1Tag2 mouse model
of cancer, producing tumors that are invasive or not, as a func-
tion of polymorphic variation in constitutional levels of GKAP
expression in the cell of origin. We further demonstrate via
GKAP knockdown that activation of NMDAR signaling, governed
by GKAP and mediated through FMRP/HSF1, promotes inva-
siveness in mouse neuroendocrine (PanNET) and in both mouse
and human ductal (PDAC) cancer cell lines.We also identify gene
expression signatures associated with GKAP-mediated NMDAR
signaling and its pharmacological inhibition that reveal striking
prognostic associations in various cancer types.
As part of a multi-protein scaffold involved in transmitting
ligand-induced signals from NMDAR, GKAP protein interacts
with a number of other synaptic scaffold proteins. Thus, GKAP
is considered to be an adaptor between the core synaptic
NMDAR complex and subsynaptic signaling molecules in neu-
rons. We envision that GKAP similarly orchestrates diverse
functional effects in cancer cells as a result of connecting down-
stream effectors with the NMDAR, thereby affecting multiple
signaling circuits. The finding that a SNP in the HSF1 binding
site of Dlgap1 might contribute to the differential expression of
GKAP between the B6 and C3H backgrounds echoes a previous
study in which a SNPwithin an intron of a gene resident in a super
enhancer region affected binding of a transcription factor and
hence gene expression, and in turn susceptibility to neuroblas-
toma (Oldridge et al., 2015). While the Dlgap1 SNP we identified
is not conserved in humans, bioinformatic analysis has found a
number of SNP sites in the human DLGAP1 promoter/enhancer
regions that overlap with potential HSF1 binding sites (data not
shown). Whether these SNPs might be associated with differen-
tial GKAP expression and/or prognosis in cancer patients is
worthy of future investigation.
NMDAR is instrumental in learning and memory through regu-
lating synaptic plasticity, which involves extensive de novo pro-
tein synthesis (Hoeffer and Klann, 2009). NMDAR activation hasMouse and Human PDAC Cell Lines
1 andmPDAC-2263 cell lines. The numbers indicate quantification (n = 3). Right
, Bonferroni’s multiple comparisons test (right panel): ****p < 0.0001 (mean ±
two independent experiments).
ssays. The data were normalized to each corresponding ‘‘control’’ in the same
: n.s., not significant; *p < 0.05 (mean ± SEM, n = 3 invasion assay devices per
C cell lines, DanG and SUIT2 (D). The knockdown efficiency was assessed by
PDH. Cell invasiveness in the invasion assays is shown in bar graphs. Repre-
that reached the other side of the membrane of a Boyden chamber (scale bar,
ired t test (D): *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. For all invasion
EM. Two independent experiments.
ated hPDAC cells. The numbers below indicate levels of p-HSF1 and FMRP
in DanG cells and SUIT2 cells are shown in the left panels. The numbers below
ssays of hPDAC cells after HSF1 or FMRP knockdown are shown in bar graphs
say devices/condition in one experiment). Two independent experiments were
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Figure 6. The NMDAR/GKAP/FMRP/HSF1 Signaling Axis Is Active in PDAC Tumors
(A) IHC staining of GKAP, FMRP, and HSF1 in both primary tumors (upper panels) and liver metastases (lower panels) from a PDAC GEMM. The primary tumor
panels are representative of >5 tumor fields per pancreas from >20 mice. The liver metastasis panels are representative of two liver macro-metastases (1 cm in
diameter).
(B) IHC staining of p-GluN2b, GKAP, FMRP, and HSF1 in hPDAC tumors displayed in a tissue microarray. Lower table: quantification of immunostaining (per-
centage) in each tissue section. Wilcoxon rank-sum test.
(C) Correlation between GKAP, FMRP, HSF1, and tumor size with p-GluN2b. Spearman’s correlation coefficient.
(D) Correlation between vascular invasion by cancer cells, classified as absent (V0) or present (V1) with p-GluN2b. Wilcoxon rank-sum test.been shown to increase translation of certain proteins without
affecting their mRNA levels. While protein translation is
frequently implicated in proliferation, several lines of evidence
have demonstrated an additional role in cancer invasion and746 Cancer Cell 33, 736–751, April 9, 2018metastasis (Hsieh et al., 2012). Moreover, localized translation
contributes to invadopodia formation (Klemke, 2012), and
FMRP has been shown to localize mRNA to invadopodia (Mili
et al., 2008), consistent with the important role FMRP plays in
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localized translational activities in neurons. As the name implies,
FMRP is best known for its association with the fragile X mental
retardation syndrome (FXS), where its loss of expression leads to
abnormal synaptic function and resultant impairment in learning
and memory. FMRP regulates mRNA translation of several com-
ponents of the NMDAR interactome (Darnell and Klann, 2013),
and decreased NMDAR-dependent synaptic activity has been
reported in Fmrp knockout mice (Bostrom et al., 2015). Intrigu-
ingly, FXS patients, who have reduced FMRP protein expres-
sion, were previously reported to have a reduced overall cancer
incidence (Schultz-Pedersen et al., 2001), and FMRP was also
implicated in aggressiveness of breast cancer (Luca´ et al.,
2013). Now our report further establishes a mechanistic founda-
tion for FMRP in cancer. We showed that FMRP activation is
downstream of the NMDAR/GKAP signaling complex and is
functionally involved in the invasive phenotype. Interestingly,
while we identified FMRP in mouse neuroendocrine tumors,
FMRP overexpression is also evident in certain other cancer
types, including PDAC (our results), cervical cancer (Jeon
et al., 2011), and breast cancer (Luca´ et al., 2013), suggesting
a broader role in epithelial tumors.
The transcription factor HSF1 orchestrates malignant pheno-
types of various tumors (Mendillo et al., 2012). Here, we further
highlight the importance of HSF1 activity in invasion via its inter-
connection with the NMDAR pathway. Interestingly, HSF1 may
sit both upstream and downstream of NMDAR/GKAP: on the
one hand its activity is upregulated by NMDAR/GKAP signaling,
while on the other it is implicated in a positive feedback loop that
regulates GKAP expression via the HSF1 binding sites within the
GKAP gene. Similarly, we show that NMDAR/GKAP signaling in-
creases expression of FMRP protein, whereas other reports
have shown that FMRP regulates translation of GluN2b and
additional components of the NMDAR signaling apparatus in
neurons (Bostrom et al., 2015), suggestive of a feedback cir-
cuitry. In addition, the regulation and interaction between HSF1
and FMRP (and related family proteins) might be reciprocal
and complex as well (Ascano et al., 2012; Santagata et al.,
2013); it will be of interest in future studies to further characterize
the functional roles and regulatory control of HSF1 and FMRP
(and the details of their interconnections).
It is notable that the NMDAR signaling axis is highly complex,
regulated at multiple levels to allow for fine-tuning of neuronal
activities. In addition to the GKAP-dependent GluN2b (NR2b)
subunit, which we have implicated in this study, there are several
other NMDAR subunits that can alternatively assemble into the
heterotetrameric receptor. The obligatory subunit NR1/GluN1(B) Mouse strain signature. The heatmap showsmajor drivers of the strain signatur
scores of sample groups. The boxmarks the 25th to 75th percentiles, and thewhis
median. No data point is beyond the limit of lines. Genes with jZj > 9 in the signa
(C) MK801 treatment signature. The heatmap shows the 330 MK801 treatment s
control tumors, and the boxplot illustrates the standardized signature scores of
showminimum tomaximum. The line in themiddle of the box indicates themedian
shown. Red, upregulated in MK801-treated B6 tumors; blue, upregulated in B6 c
(D) GSEA analysis revealed that the MK801 treatment signature showed high e
downregulated gene sets.
(E) Leading edge analysis from (D) identified 148 common driver genes in both M
pathwaylow signature. Shown here are the ‘‘core’’ common driver genes, which hav
C3H tumors; blue, upregulated in B6 controls.
See also Figure S3, Tables S1, S2, S3, and S4.
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GluN2d) and two more NR3/GluN3 subunits (GluN3a, GluN3b).
Among these, GluN2a and GluN2b are the most commonly ex-
pressed in neurons, but the relative levels and potential func-
tional roles of each subunit in cancer remain to be investigated.
These NMDAR subunits have different intracellular C-terminal
domains, allowing for preferential association with different
downstream scaffold proteins (Paoletti et al., 2013). Additionally,
three of nine differentially spiced isoforms of GKAP are (differen-
tially) expressed in the mPanNETs. Interestingly, it has been
shown that splice variants of DAP102, another scaffold protein
of NMDAR, differentially regulate NMDAR trafficking in a sub-
unit-dependent manner (Wei et al., 2015). As such, it remains
to be explored whether some or all GKAP isoforms specifically
contribute to invasive tumor growth in this and other cancer
types. Moreover, Dlgap1 is one of the five members of the Dlgap
gene family (Dlgap1–Dlgap5); whether others can contribute to
NMDAR activity in tumors also remains to be elucidated.
Given this complexity, single-gene-based assessment of
GKAP or of the core NMDAR signaling components in tumor
samples is not certain to be informative about pathway
activity and its association with prognosis. Rather, it will be
auspicious to begin prognostic assessment with identification
of NMDAR pathway-high versus pathway-low tumors using the
MK801-treatment/NMDAR-pathwaylow signatures described
here. Then, for tumors showing a pathway-high association, in-
dividual genes in the NMDAR signaling axis could be profiled,
noting the proviso that some components are regulated post-
transcriptionally, by translational control, by phosphorylation,
and potentially by alternative mRNA spicing.
In conclusion, we have presented several lines of evidence
that reveal howdifferential expression of GKAP promotes cancer
invasion through modulating the NMDAR pathway. The results
conceptually expand and extend previous studies documenting
activity of NMDAR signaling in cancer and the benefits of its
pharmacological inhibition, suggesting that co-option of this
neuronal signaling pathway to promote malignant growth may
prove to be a relatively common phenomenon.
Preclinical trials in the mouse model of PDAC with NMDAR in-
hibitors, one of which (memantine) is clinically tractable, suggest
that therapeutic targeting of NMDAR signaling may have benefit
in this highly malignant form of human cancer. Notably, the
extended survival plateau in PDAC patients with an MK801
treatment signature indicative of non-induced/repressed gluta-
mate-NMDAR signaling is very striking, considering that the
overall 5-year survival rate is only 6% in PDAC patients; similare (fold change >2; jZj > 9) and the boxplot illustrates the standardized signature
kers showminimum tomaximum. The line in themiddle of the box indicates the
ture are shown. Red, upregulated in B6; blue, upregulated in C3H.
ignature genes, which segregated MK801-treated B6 tumor samples from B6
sample groups. The box marks the 25th to 75th percentiles, and the whiskers
. No data point is beyond the limit of lines. Geneswith jZj > 9 in the signature are
ontrol tumors.
nrichment when compared with the strain signature. p = 0 for both up- and
K801 treatment signature and mouse strain signature, representing NMDAR-
e jZj > 3 in both signatures. Red, upregulated inMK801-treated B6 tumors and
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Figure 8. Activity of the NMDAR Signaling Pathway is Associated with Poor Prognosis in Human Cancer Types as Assessed in the TCGA
Patient Cohort
(A) MK801 (left panel) and memantine (right panel) treatments in PDAC GEMM. (Left) Control group: 28 mice; median survival, 23 days after enrollment. MK801
group: 25 mice; median survival, 36 days after enrollment. p = 0.0206, log rank test. (Right) Control group: 35 mice; median survival, 13.4 weeks. Memantine
group, 33 mice; median survival, 15.4 weeks. Log rank test, *p < 0.05.
(B) Survival analysis employing the mPanNET MK801 treatment signature in PDAC patients (n = 13 for associated, n = 165 for not associated). Kaplan-Meier
analysis with log rank p value shown.
(C) Cox regression analysis in PDAC patients, both in univariate and multivariable analyses while controlling for other clinical covariates. HR, hazard ratio; CI,
confidence interval; T score, primary tumor size/invasiveness; N score, lymph node metastasis; Pinteraction, p value of interaction between significant covariates
(model comparison; likelihood ratio test).
(D) Survival analysis employing MK801 treatment signature in patients from several cancer types in addition to PDAC, including glioma (combining low-grade
glioma and glioblastoma) and kidney cancers (combining three major subtypes of kidney cancer: chromophobe renal cell carcinoma, clear cell renal carcinoma,
and papillary kidney carcinoma). All patients were included in each cancer type shown, regardless of treatment and staging. Brain cancer, associated, n = 566; not
associated, n = 93. Kidney cancers, associated, n = 684; not associated, n = 197.
(E) Empirical cumulative distribution function (CDF) plot demonstrating the association of low-grade gliomas (LGG; marked in blue) compared with high-grade
glioblastomas (GBM; marked in red) with the (pathway-low) MK801-treatment signature (p < 2.22e-16; Kolmogorov-Smirnov test).
(F) Survival analysis employing NMDAR-pathwaylow signature in PDAC patients (n = 13 for associated, n = 164 for not associated). Kaplan-Meier analysis with log
rank p value shown.
(legend continued on next page)
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associations in other tumor types are also provocative. Thera-
peutic targeting of NMDAR signaling may therefore have prom-
ise in a precision medicine strategy focused on patient subsets
whose tumors express the core NMDAR pathway genes,
including GKAP, but lack the MK801 treatment signature, which
predicts impaired NMDAR signaling (and hence therapeutic non-
responsiveness and better prognosis), so as to focus on poten-
tially responsive at risk cohorts. Finally, we have begun in this
study to chart the downstream pathways that orchestrate the
invasive growth phenotype driven by GKAP-modulated gluta-
mate-NMDAR signaling, implicating two effectors, FMRP and
HSF1, in distinctive forms of pancreatic cancer.
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Software and Algorithms
Graph Pad Prism 7.0 Graphpad RRID:SCR_002798
MetaCore Thomson Reuters
https://portal.genego.com/
RRID:SCR_008125
Independent Component Analysis for RNA-seq data This paper. N/A
Other
Millicell-PCF 8.0mm insert 12mm diameter Millipore #PI8P01250
Growth factor reduced matrigel, phenol red free 10 ml BD Bioscience #356231
Rat tail collagen type I ABOVE 4.0 ug/ml 100 ml BD Bioscience #354236
Vectastain Elite ABC kit Vector Labs #PK-6100
DAB Sigma-Aldrich #D5637-1G
Signal Stain Antibody Diluent Cell Signaling #8112CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Douglas
Hanahan (douglas.hanahan@epfl.ch).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All studies involving mice were approved by the committee for animal research of Canton Vaud, Switzerland, in accordance with the
Swiss regulation of experimental animal welfare. All mice used in this studyweremaintained in theCenter of Phenogenomics at EPFL.
Cell Culture
bTC-B6 (bTC-PO1) and bTC-C3H were derived by former members (Peter Olson andMatthew G. Chun, respectively) in the Hanahan
lab, from B6 and C3H PanNETs, respectively. Both lines were cultured in DMEM (Life Technology #41965) with 10 % FBS and pan-
strep. The bTC-C3H line was maintained at low passage number, particularly for the flow-based invasion assay, preferably less than
20 passages. All the cell lines described in this paper were cultured using the same culture conditions.
Intervention Trial with MK801 in RIP1Tag2 Mice
Intervention trials were performed as described previously (Li and Hanahan, 2013). Only male mice were included in the trial, as the
tumor burden is significantly different between male and female RIP1Tag2 mice (Chun et al., 2010). The trials start at 10.5 weeks and
end at 14 weeks. Saline or MK801 (1 mg/kg) was injected intraperitoneally daily for 5 days a week. At end point, the mice were car-
diac-perfused with normal saline followed by zinc formalin, and the tissues were harvested. The PanNETs were measured by caliber,
and the volume of each tumor was calculated by the following formula: (short axis)2 x (long axis) x 0.52. The total tumor burden rep-
resents the cumulative tumor burden from all tumors in the pancreas.
Survival Trial with MK801 and Memantine in PDAC Mice
A mouse model of pancreatic ductal adenocarcinoma (LSL-KrasG12D; p53LSLR172H; p48cre (Hingorani et al., 2005)) was used for
the survival analysis. Different treatment schemes have been utilized for PDAC preclinical trials (Gopinathan et al., 2015): for early
intervention/survival trials, PDACmice were typically enrolled from 10-12 weeks of age (Miller et al., 2015; Olson et al., 2011); for later
intervention/survival trials, PDACmice weremonitored by ultrasound regularly, until the enrolment sizes were reached.We employed
the early intervention/survival trial scheme for MK801 trial. Both male and female mice were included. Whenever possible, gender-
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started from 10.5 weeks onwards. MK801 was diluted in normal saline, and administrated at 1 mg/kg, once daily, i.p., 5 days a week.
For the MK801 trial, when the mice reached 14 weeks old, they were given a one-week drug break in order to mitigate drug-related
toxicity. Thereafter, the mice were dosed for 3 days a week from 15 weeks old until the end stage. Memantine was diluted in normal
saline, and administered at 10 mg/kg, once daily, i.p., 5 days a week, continuously from 10.5 weeks until the animal reached end
point. Weight loss of more than 15 % of initial body weight, or the development of severe ascites, was considered to dictate end
points.
METHOD DETAILS
Invasion Assay
As described previously (Li and Hanahan, 2013). A gel composite of 1.2 mg/ml rat tail collagen type I and 10%growth factor reduced
matrigel was prepared. The final gel/cell mixture will be 500 ml for each set of technical triplicates, with 275 ml of gel, 125 ml of cell
suspension (at 2 million/ml), and either 100 ml of medium or 100 ml of 500 mMMK801 diluted in medium (so that the final concentration
of MK801 will be 100 mM). Ice-cold pipette tips were used whenever they need to be in contact with the gel, and the gel was kept on
ice until adding to the insert. 150 ml gel/cell mixture per well was placed onto transwell inserts. The gel/cell mixture was added to the
side of the transwell, avoiding direct contact of the membrane. The inserts were placed into 24 well plates, then put into the 37C
incubator for 40 min - 1 hr until the gel solidified. After incubation, plates were removed and for static conditions: medium was
added (150 ml) to the top of the gel and underneath the transwell (650 ml); for flow conditions: medium was added (650 ml) to the
top of the gel and underneath the transwell (150 ml). Only serum-free medium (DMEM) was used in the whole device. After overnight
incubation (16-18 hr), inserts and medium were removed, and the gels were wiped with cotton tips while avoid disturbing the bot-
tom side of the membrane followed by fixation with ice-cold methanol and washes with PBS for three times. DAPI staining was used
for visualization of nuclei under upright microscope. The results were quantified using Fiji.
Immunohistochemical Staining
As described previously (Li and Hanahan, 2013). Zinc-formalin-fixed, paraffin-embedded tissue sections were used. Mice were intra-
cardially-perfused with PBS and zinc-formalin before tissue harvest. Slides were immersed in citrate buffer (pH = 6.0) for antigen
retrieval for 20 min at 95C. Endogenous peroxidase activity was blocked with 3 % H2O2 in PBS for 10 min at room temperature.
Protein blocking was done 1 hr at room temperature with 5 % normal donkey serum in 0.1 %TBST. Primary antibodies were incu-
bated in the cold roomovernight in blocking buffer, followed by biotinylated secondary antibodies incubation at room temperature for
30 min, then by incubation with avidin/biotinylated complex for 30 min at room temperature. 0.1 % TBST was used as wash buffer.
DAB was used for visualization for 8 min at room temperature. After washes, stained slides were counterstained with Meyer’s hema-
toxylin. For HSF1 IHC, Signal Stain Antibody Diluent was used as suggested on the antibody datasheet.
Transcription Factor Prediction
SNPs were retrieved from the SNP query tool of MGI at http://www.informatics.jax.org/javawi2/servlet/WIFetch?page=snpQF.
Within the Dlgap1 gene and its 2Kb upstream, ‘‘different’’ SNPs between C57BL/6 (reference) and C3H/HeJ strains were selected
(205 dbSNP from Build 137 entries). These SNP sites were subjected to further analysis using FIMO (Grant et al., 2011) with Transfac
2012 Position Weight Matrices (PWM) to predict transcription factor binding.
Chromosome Immune-Precipitation (ChIP) Assay
ChIP was performed as described previously (Mendillo et al., 2012), with several modifications. After immunoprecipitation, enrich-
ments were determined using SYBRSelect Master Mix for CFX (Life Technologies) on the CFX96 Real-Time PCR Detection System
(Bio-Rad). Enrichments were verified using two biological replicates, each with two ChIP experimental replicates, followed by ChIP-
qPCR in duplicate. The primer pairs used were: HSP70 (Hspa1a) (forward: 5’-TCCAGCAGTTTCGCGTCTG-3’; reverse: 5’-TCC
GTACTCTCCAGTGAACCC-3’); potential HSF1 binding element on the GKAP gene (forward: 5’-CATTTTAAAACTAGGCCCAAACT
CAGC-3’; reverse: 5’-AGAGAATATTTCTTCCCCAGGTAGGAT-3’); b-maj (Hbb-b1) (forward: 5’-GGGAGAAATATGCTTGTCATC-3’;
reverse: 5’-CAACTGATCCTACCTCACCTT-3’). In brief, for cell lines, cell numbers were counted after trypsinization, and crosslinked
with 1 % formaldehyde solution (Sigma) in 10 % FBS/PBS. The cell pellets were resuspended in sonication buffer (10 mM Tris-HCl,
pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1 % Na-Deoxycholate, 0.5 % N-lauroylsarcosine, 13 protease inhibitors), and
sonicated with a Bioruptor Next Gen (Diagenode). After sonication, TritonX was added to a final concentration of 1 %. DNA concen-
tration was measured with Qubit dsDNA BR Assay kit (Life Technologies, #Q32850) on the Qubit Fluorometer (LifeTechnologies).
Sonicated DNA was incubated with anti-HSF1 antibody (Santa Cruz, #9144) at 4C overnight with rotation. On the next day, 25 ml
Pierce Protein A/G Magnetic beads (Thermo Scientific, #88803) were added to each sample, and rotated at 4C for 1.5 hour. The
beads were then washed with the following buffers: 6X with low salt washing buffer (Noordermeer et al., 2011), 2X with high salt
washing buffer (Noordermeer et al., 2011), 2X with LiCl washing buffer (Noordermeer et al., 2011), and 2X with TE + 50 mM NaCl.
Finally, the beads were eluted with 210 ml elution buffer (Lee et al., 2006) at 65C for 30 minutes, with vortexing every 5 minutes.
The crosslink was reversed by incubating samples at 65C overnight. DNA purification was done according to previous protocol
(Lee et al., 2006), and DNA concentration was measured with the Qubit dsDNA HS Assay kit (Life Technologies).e3 Cancer Cell 33, 736–751.e1–e5, April 9, 2018
Western Blotting
Transfer was performed using nitrocellulosemembrane (GE Healthcare), and blocked with 5%BSA in 0.1% TBST. Primary antibody
was diluted in the same blocking buffer and incubated at either room temperature for two hours or 4C overnight, and secondary
antibody was incubated for 1 hour at room temperature in blocking buffer, followed by visualization with SuperSignal West Pico
Chemiluminescent Substrate (Pierce, #34077). Imaging was done on the Fusion Fx7 imaging platform for fluorescence and chem-
iluminescence (PEQLAB, Germany), and quantification was performed using build-in software and Fiji. Background subtraction
was performed using the rolling-ball algorithm. After quantification, images were inverted to black signal/white background, and
adjusted for better visualization using Photoshop.
Electrophysiology
Cells were bathed in a magnesium-free Ringer solution, containing (mM): 140 NaCl, 2.5 KCl, 2 CaCl2, 10 glucose, 0.01 glycine, 10
HEPES/Na, pH adjusted to 7.4 with NaOH. For whole-cell recording, patch pipettes were filled with a solution containing 105 K glu-
conate, 30 KCl, 10 HEPES/KOH, 4 ATP / Mg, 0.3 GTP Na2, 10 creatine phosphate / Na, pH adjusted to 7.3 with NaOH. Membrane
potentials were corrected for liquid junction potential nulled before seal formation. Whole-cell recordings were established using an
Axopatch 200A patch-clamp amplifier (Axon Instruments) in capacitative feedback mode for low noise, low-pass filtered at 5 kHz
(Bessel, 8-pole) and sampled at 20 kHzwith 16-bit resolution using aNational Instruments X-series board. Further low-passGaussian
filtering at corner frequencies between 500 Hz – 1 kHz was applied offline. Glutamate and NMDA responses were elicited by pressure
ejection of agonist dissolved in the Ringer solution, through pipettes with tip diameters of 10-20 mm, and pressures steps of
5-10 mbar.
Intracellular Calcium Measurement
For recording calcium signals, cells were loaded with the fluorescent indicator Oregon Green 488 BAPTA-1 AM (Life Technologies) at
5 mM for 1 hour, and imaged using epifluorescence (Olympus IX71 microscope, UMPlan FI 10X objective, X-Cite 120 light source,
EXFO Photonic Solutions), and a sCMOS camera (Zyla 4.2P, Andor). Using the Matlab Image Processing toolbox (Mathworks),
cell regions were selected, and the average signals across pixels in each region were analysed as the change in fluorescence
(DF) relative to the baseline level (F), i.e. DF/F.
RNA-Seq Sample Collection (B6/C3H/MK801)
mPanNETs were collected from RIP1Tag2 mice ranging from 14-16 week old (end stage). Control mice were either not treated, or
treatedwith normal saline (‘‘sal’’) for 3 days prior to sacrifice;MK801-treatedmicewere treated for 3 days prior to sacrifice. Harvested
tumors were snap-frozen in liquid nitrogen, before being processed for RNA-extraction. The miRNeasy kit (QIAGEN) was used for
RNA extraction. Tissue homogenization was done on TIssueLyser II (QIAGEN) in pre-cooled cassettes, with disposable beads in
700 ml Qiazol (from the miRNeasy kit)/ tumor. On-column DNase digestion (QIAGEN) were performed for all samples during RNA
extraction according to manufacturer’s protocol.
Antibodies
GluN2b (Pierce #PA3-105) for IP, WB and IHC, (NeuroMab #75-097, 75-101) for WB; GKAP (Sigma # PRS4623) for IHC, IP, and WB
1:1000 in mouse, (R&D #MAB7296) for IHC in human PDAC; FMRP (Cell Signaling, #4317); HSF1 (Santa Cruz, #sc-9144) for ChIP,
(Cell Signaling, #4356) for IHC 1:50.
siRNA Knockdown of Human PDAC Cell Line
100 pmol commercially available siRNA (Life Technologies) was transfected with 5 ml Lipofectamine 2000/well in 6 well plates. Data
was analyzed 30 hours post transfection.
QUANTIFICATION AND STATISTICAL ANALYSIS
RNA-Seq Analyses
Illumina HiSeq 2500 101-nt single-ended reads were mapped to the UCSC mm9 mouse genome build (http://genome.ucsc.edu/)
using RSEM (Li and Dewey, 2011). Raw estimated expression counts were upper-quartile normalized to a count of 1000 (Bullard
et al., 2010). Given the complexity of the dataset in terms of a mixture of different biological conditions, a high-resolution signature
discovery approach was employed to characterize global gene expression profiles. Independent Component Analysis (ICA), an un-
supervised blind source separation technique, was used on this discrete count-based expression dataset to elucidate statistically
independent and biologically relevant signatures (Dimitrova et al., 2016; Li et al., 2015). ICA is a signal processing and multivariate
data analysis technique in the category of unsupervised matrix factorization methods.
Conceptually, ICA decomposes the overall expression dataset into independent signals (gene expression patterns) that represent
distinct signatures. High-ranking positively and negatively correlated genes in each signature represent gene sets that drive the cor-
responding expression pattern (in either direction). Multi-sample signatures were visualized using relative signature profile boxplots.
Biologically relevant and statistically significant signatures were identified using aMann-Whitney U test. Each signature is two-sided,
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Formally, utilizing input data consisting of a genes and samples matrix, ICA uses higher order moments to characterize the dataset
as a linear combination of statistically independent latent variables. These latent variables represent independent components based
on maximizing non-gaussianity, and can be interpreted as independent source signals that have been mixed together to form the
dataset under consideration. Each component includes a weight assignment for each gene that quantifies its contribution to that
component. Additionally, ICA derives a mixing matrix that describes the contribution of each sample towards the signal embodied
in each component. This mixing matrix can be used to select biologically relevant signatures among components with distinct gene
expression profiles across the set of samples. The R implementation of the core JADE algorithm (Joint Approximate Diagonalization
of Eigenmatrices) (Biton et al., 2013; Miettinen et al., 2017; Rutledge and Jouan-Rimbaud Bouveresse, 2013) was used along with
custom R utilities. All RNA-seq analyses were conducted in the R Statistical Programming language (http://www.r-project.org/). Iso-
form-level differential analyseswere performed using EBSeq (Leng et al., 2013). Gene set enrichment analysis (GSEA) was carried out
using the pre-ranked mode with default settings (Subramanian et al., 2005). Enrichment maps were generated using the EM (Merico
et al., 2010) plugin for Cytoscape (Shannon et al., 2003). Heatmaps were generated using the Heatplus package in R. For the deri-
vation of common driver genes in the strain and the MK801 treatment signatures, GSEA leading edge analyses (Subramanian et al.,
2005) were performed by using the ranked gene list from the strain signature to interrogate against the driver genes (defined by jZj>3)
in the MK801 treatment signature, and vice versa. The union of these two analyses was taken as the common driver genes.
Clinical Data Analysis
Genes with standardized signature correlation scores jzj > 3 were used as gene sets to score TCGA (https://tcga-data.nci.nih.gov/
tcga/) patient datasets using ssGSEA (Barbie et al., 2009). Patient tumors were stratified using standardized scores and Kaplan-
Meier survival analyses were conducted to compare the top scoring patients (within 3.5 of the top Z score) with the low scoring
patients (within 3.5 of the bottom Z score) to assess differences in survival time. P values from the log-rank test are reported. Cox
proportional hazards analysis was conducted across all patients in the TCGAPDAC cohort (with survival greater than 30 days to elim-
inate possible complications arising from surgical intervention) to asssess the prognostic significance of the signature while control-
ling for various clinical covariates. Hazard ratio proportionality assumptions for the Cox regressionmodel fit were validated by testing
for all interactions simultaneously (p=0.422). All survival analyses were conducted using the survival package in R.
Statistics
Statistics was performed usingGraphPad Prism. In general, when technical replicates were shown for in vitro experiments, student-t-
test was used for statistic analysis, and the same experiment was at least repeated once with similar trend observed.When data from
multiple experiments was merged into one figure, Mann-Whitney test was performed. If each experiment was normalized to its in-
ternal control, then one-column t-test was performed. For in vivo experiments, Mann-Whitney test was used. ANOVA with post-
hoc test was performed when analyzing experiments with multiple variants. Detailed statistic methods for each figure can be found
in corresponding figure legends. The Kolmogorov-Smirnov test was used to assess statistical significance in ECDF plots.
DATA AND SOFTWARE AVAILABILITY
The RNA-seq data for mPanNETs has been deposited in the GEO database under ID codes GSE102598.e5 Cancer Cell 33, 736–751.e1–e5, April 9, 2018
